Pyrvinium Pamoate for Pancreatic Cancer

Thomas Jefferson University, Philadelphia, PA
Pancreatic Cancer+7 More ConditionsPyrvinium Pamoate - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a drug to treat pancreatic cancer that cannot be removed by surgery. The drug may help patients live longer.

Eligible Conditions
  • Pancreatic Cancer
  • Stage I Pancreatic Cancer
  • Stage IIB Pancreatic Cancer
  • Stage IA Pancreatic Cancer
  • Stage 0 Pancreatic Cancer
  • Stage IB Pancreatic Cancer
  • Stage II Pancreatic Cancer
  • Stage IIA Pancreatic Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

1
Hafnium Oxide-containing Nanoparticles NBTXR3
1
Hypofractionated Radiation Therapy
1
Stereotactic Hypofractionated Radioablation

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 30 days from last dose

Completion of treatment
Profile of pyrvinium pamoate (PP)
Day 30
Incidence of dose limited toxicity (DLT)
Up to 4 weeks
Bioavailability of PP
Fatty tissue accumulation of PP

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
Hafnium Oxide-containing Nanoparticles NBTXR3
1
Hypofractionated Radiation Therapy
1
Stereotactic Hypofractionated Radioablation

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

1 Treatment Group

Treatment (pyrvinium pamoate)
1 of 1

Experimental Treatment

18 Total Participants · 1 Treatment Group

Primary Treatment: Pyrvinium Pamoate · No Placebo Group · Phase 1

Treatment (pyrvinium pamoate)
Drug
Experimental Group · 1 Intervention: Pyrvinium Pamoate · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 30 days from last dose

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
416 Previous Clinical Trials
136,796 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Male participants must use protection (like condoms) during sexual activities.
References

Frequently Asked Questions

Does Pyrvinium Pamoate have any harmful side effects?

"Given that this is a Phase 1 trial with limited data surrounding its safety and efficacy, our team at Power has given Pyrvinium Pamoate a score of 1." - Anonymous Online Contributor

Unverified Answer

Is there a significant body of scientific research on Pyrvinium Pamoate?

"At the moment, there is only 1 active clinical trial for Pyrvinium Pamoate. This is a Phase 3 trial. The majority of research surrounding Pyrvinium Pamoate is conducted in Philadelphia, with 1 other location running similar studies." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top